- Home
- TXO vs ATXS Comparison
TXO vs ATXS Comparison
Compare TXO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- ATXS
- Stock Information
- Founded
- TXO 2012
- ATXS 2008
- Country
- TXO United States
- ATXS United States
- Employees
- TXO N/A
- ATXS N/A
- Industry
- TXO Oil & Gas Production
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- ATXS Health Care
- Exchange
- TXO Nasdaq
- ATXS Nasdaq
- Market Cap
- TXO 700.0M
- ATXS 584.1M
- IPO Year
- TXO 2023
- ATXS 2015
- Fundamental
- Price
- TXO $16.62
- ATXS $9.56
- Analyst Decision
- TXO Strong Buy
- ATXS Strong Buy
- Analyst Count
- TXO 2
- ATXS 5
- Target Price
- TXO $26.00
- ATXS $28.00
- AVG Volume (30 Days)
- TXO 164.8K
- ATXS 380.9K
- Earning Date
- TXO 11-05-2024
- ATXS 11-13-2024
- Dividend Yield
- TXO 14.28%
- ATXS N/A
- EPS Growth
- TXO N/A
- ATXS N/A
- EPS
- TXO N/A
- ATXS N/A
- Revenue
- TXO $285,451,000.00
- ATXS N/A
- Revenue This Year
- TXO N/A
- ATXS N/A
- Revenue Next Year
- TXO $28.33
- ATXS N/A
- P/E Ratio
- TXO N/A
- ATXS N/A
- Revenue Growth
- TXO N/A
- ATXS N/A
- 52 Week Low
- TXO $15.22
- ATXS $6.20
- 52 Week High
- TXO $23.56
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- TXO 41.69
- ATXS 42.48
- Support Level
- TXO $15.22
- ATXS $9.17
- Resistance Level
- TXO $17.05
- ATXS $9.99
- Average True Range (ATR)
- TXO 0.62
- ATXS 0.60
- MACD
- TXO -0.02
- ATXS -0.02
- Stochastic Oscillator
- TXO 54.25
- ATXS 21.20
About TXO TXO Partners L.P. Common Units Representing Limited Partner Interests
TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.